In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
New developments in anti thrombotic drug therapy
Session

Event : ESC Congress 2019

Topic : Antiplatelet Drugs

  • Session type : Advances in Science
  • Date : 01 September 2019
  • Time : 18:40 - 19:50

4 presentations in this session

State of the Art - Novel targets in anti thrombotic drug development

Event : ESC Congress 2019

  • Session : New developments in anti thrombotic drug therapy
  • Speaker : B Rocca (Rome,IT)

Novel direct thrombin inhibitor achieves superior antithrombotic effect with lower bleeding risk than heparin or bivalirudin

Event : ESC Congress 2019

  • Session : New developments in anti thrombotic drug therapy
  • Speaker : CY Koh (Singapore,SG)

Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452

Event : ESC Congress 2019

  • Session : New developments in anti thrombotic drug therapy
  • Speaker : L Jennings (Memphis,US)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are